Good MorningEquities ended the month of November on solid footing boosted by remarks by Fed chief Jerome Powell. Mr. Powell signaled the FOMC may shift its stance as soon as the next meeting and slow the pace of interest rate hikes. While the market cheered the news the takeaway is that inflation is still running hot and underpinned by rising wages. In this light, the pace of hikes may have slowed but it is not going to end any sooner than previously indicated. The risk now is that inflation will only subside moderately and prolong the time it takes for the FOMC to do its job.
Today's news may alter the entire FOMC outlook once again so don't be surprised if the market makes an about face. The PCE price index is expected to cool from the previous month but may not have cooled as much as expected. Regardless, the index is expected to support the current outlook for interest rate hikes which is having a negative impact on the outlook for S&P 500 earnings. While this dynamic is overshadowing the market no rally should be trusted. Featured: Your Money Is Now ‘Government Property’ (Their Words) (Ad) 
|
Markets | | |
Shares of Cosmos Holdings (NASDAQ: COSM) stock are up 618% in November. This penny stock has gone from trading for actual pennies per share to 68 cents per share at the time of this writing. The company has had some favorable news to report. But this has all the earmarks of a short squeeze.
... Read the Full Story |
|
From Our Partners | | A Historic Gold Announcement Is About to Rock Wall Street?
For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time could validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains. | | Click here to get Garrett’s Top Four picks now. |
|
Markets | | | Updated: Federal Reserve Chairman Jerome Powell confirmed Wednesday, Nov 30, that smaller interest rate increases are likely ahead even as he sees progress in the fight against inflation as largely inadequate.We are approaching that time of year when the stock market gets into a holiday mood tr... Read the Full Story |
|
Stocks | | |
Results from Crowdstrike (NASDAQ: CRWD) and NetApp (NASDAQ: NTAP) have brought dark clouds to the cloud-stock universe. While both companies had good CQ3 periods the outlook for the rest of the year is gloomy indeed. The news has both stocks down double digits but this may be an opportunity. Analy... Read the Full Story |
|
From Our Partners | | For over four decades, I’ve been using my proprietary stock rating system to help me find the most explosive opportunities… BEFORE they take off for unbelievable gains.
I found Amazon in 2003, before it exploded almost 100 times higher… Cisco in 1992, before it jumped 123 times higher… Adobe in 1990, before it jumped 280 times higher...
Apple in 1988, before it jumped 617 times higher… Microsoft in 1988, before it skyrocketed more than 1,000X…
And Nvidia in 2019, before shares exploded as high as 3,423%. | | My system has rated these three stocks as an immediate buy for 2025. |
|
Politics | | | Asian shares were mostly higher on Wednesday, ahead of a closely watched speech by the Federal Reserve chief that may give clues about future interest rate hikes.
Investors were also eyeing developments in China, where protests have erupted over the “zero-COVID” strategy that has con... Read the Full Story |
|
Politics | | | Wall Street closed out a solid November with a broad market rally Wednesday after the head of the Federal Reserve said the central bank could soon begin easing up on its aggressive interest rate increases aimed at taming inflation.
Fed Chair Jerome Powell, speaking at the Brookings In... Read the Full Story |
|
From Our Partners | | Everyone is focusing on AI stocks...
Yet little-known "space stocks" are rocketing to record highs with gains of 588% - 3,710%!
One new space stock that I call "the next SpaceX" is preparing to IPO on the NASDAQ.
Right now, you can grab Pre-IPO shares for less than $4.00.
And my estimates suggest the valuation could soar 457% with the IPO.
Get urgent details inside this free report... | | The Next SpaceX Pre-IPO |
|
Politics | | | The Federal Reserve will push rates higher than previously expected and keep them there for an extended period, Chair Jerome Powell said Wednesday in remarks likely intended to underscore the Fed's single-minded focus on combating stubborn inflation.
Yet in a speech at the Brookings ... Read the Full Story |
|
Politics | | | It is time for China to move away from massive lockdowns and toward a more targeted approach to COVID-19, the head of the International Monetary Fund said days after widespread protests broke out, a change that would ease the impact to a world economy already struggling with high inflation, an energ... Read the Full Story |
|
Markets | | | A heavily criticized private company that operates the transmission and distribution of power in Puerto Rico secured a last-minute extension on its contract Wednesday despite widespread objections.
Luma Energy obtained the extension following a 4-1 vote by the Puerto Rico Electric Pow... Read the Full Story |
|
Markets | | |
China-based electric vehicle maker NIO (NYSE: NIO) powered more than 19% higher Wednesday. Shares were trading at $12.51 with an hour left in the session.
NIO, along with other Chinese EV manufacturers, rose in tandem with XPeng (NYSE: XPEV), which reported a third-quarter loss of $0.36, me... Read the Full Story |
|
Stocks | | |
In what has been a tough year for growth investors, few equity categories have provided the spark counted on for portfolio appreciation. The energy sector is one, but it's a sea of red almost everywhere else.
This means two things: 1) many brokerage accounts will be limping into 2023 with lower v... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia. | | View Today's Stock Pick |
|
